NCT04176328 - Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

September 16, 2020

Study Completion Date

September 30, 2020

Conditions

Cystic Fibrosis

Interventions

DRUG

Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.

Teicoplanin Sandoz administered by inhalation (aerosol).

Trial Locations (1)

Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona, Verona